Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); this article does not constitute any investment advice. Recently, Pfizer announced that it will launch Paxlovid labeled with NDA into the market by the end of this year, while the drug labeled with EUA will continue to be provided free of charge to eligible patients until then.The five-day course of treatment is priced at $1,390.This is more than twice the price ($529) that the company charged the government during the pandemic.At the same time, Pfizer announced that it had revised the terms of the Paxlovid supply agreement signed with the U.S. government. According to the adjusted agreementThe U.S. government will return approximately 7.9 million courses of Paxlovid to Pfizer in a "non-cash transaction," indicating a decline in demand for Paxlovid.。A spokesperson for Pfizer stated: "The pricing of Paxlovid is based on its value to patients, healthcare providers, and the healthcare system." The spokesperson mentioned that company executives have made it clear from the outset that once the pandemic ends, the price for private payers will increase.In addition,Pfizer will also launch a $3.5 billion cost-cutting plan,Mainly used for paymentSeverance pay andForImplementation CostFund the reduction plan,Of which, 1 billion US dollars is expected to be achieved in 2023, and another 2.5 billion US dollars is expected to be achieved in 2024.Such a huge severance package has triggeredSpeculations in the industry about Pfizer's global layoffs. But for now,It is not yet clear how many employees will be affected,As of the end of last year, Pfizer employed approximately 83,000 people worldwide.After a sharp decline in second-quarter earnings, Pfizer's CFO once said,The company will "launch a cost improvement plan across the entire enterprise, including global layoffs."。In September this year, Pfizer China has made some adjustments:Pfizer China's vaccine division, hospital emergency division and other organizational structure adjustments; Pfizer's global oncology department reorganized into an independent business unit.References:--www.endpts.com--Company Official Website
